NCT05585684
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 8 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
- Enrollment increased: 150 → 200 participants
- Secondary endpoints: details revised at 1 of 13 entries
- Study description expanded, about 26 words
- Publications: details revised at 1 of 1 entry
- Minor Site contact updatedv9
- Notable Primary and study completion dates: Sep 2025 to Sep 2027
- Site contact updated
- Minor Study description expanded, about 1,143 wordsv5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 2023 to Jan 27, 2023
- Site details revised
Show 2 earlier versionsHide 2 earlier versions
- Minor Study title shortened, about 4 wordsv3
- Notable Start date: Nov 2022 to Feb 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Prevalence of variants in ctDNA with clinical significance across different levels of evidence
Timeframe: Up to 2 years after enrollment
Percentage of patients with a molecular tumor board (MTB) treatment recommendation
Timeframe: Up to 2 years after enrollment
Percentage of patients treated according to MTB recommendation
Timeframe: Up to 2 years after enrollment
Turnaround time from collection of liquid biopsy to MTB recommendation
Timeframe: Up to 2 years after enrollment
Time from MTB recommendation to treatment initiation
Timeframe: Up to 2 years after enrollment
Secondary (13)
Time to cancer therapy for patients who are treated according to MTB recommendation
Time to cancer therapy for patients who are not treated according to MTB recommendation
Progression free-survival of patients who are treated according to the MTB recommendations
Progression free-survival of patients who are not treated according to the MTB recommendations
Overall survival of patients who do receive treatment according to the MTB recommendations
Show 8 moreShow less
Overall survival of patients who do not receive treatment according to the MTB recommendations
MTB-based treatment recommendations stratified by therapeutic class
Proportion of deviations from treatment recommendations
Reasons for deviations from treatment recommendations
Concordance of detected alterations obtained through liquid biopsy analyses
cfDNA yield obtained
ctDNA amount obtained
Liquid biopsy assay success rate
Arms and interventions
Oncology Patients
All participants in the study.
Other: Non-invasive Comprehensive Genomic Profiling for Cancer Treatment Selection
Sites
1 site in 1 country
- Johns Hopkins UniversityBaltimore, Maryland, United States